186 related articles for article (PubMed ID: 11597832)
21. [Mechanisms of extracellular matrix remodeling in dilated cardiomyopathy].
Pauschinger M; Chandrasekharan K; Li J; Schwimmbeck PL; Noutsias M; Schultheiss HP
Herz; 2002 Nov; 27(7):677-82. PubMed ID: 12439639
[TBL] [Abstract][Full Text] [Related]
22. Matrix metalloproteinases: regulation and dysregulation in the failing heart.
Spinale FG
Circ Res; 2002 Mar; 90(5):520-30. PubMed ID: 11909815
[TBL] [Abstract][Full Text] [Related]
23. Myocardial infarct expansion and matrix metalloproteinase inhibition.
Mukherjee R; Brinsa TA; Dowdy KB; Scott AA; Baskin JM; Deschamps AM; Lowry AS; Escobar GP; Lucas DG; Yarbrough WM; Zile MR; Spinale FG
Circulation; 2003 Feb; 107(4):618-25. PubMed ID: 12566376
[TBL] [Abstract][Full Text] [Related]
24. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression.
Polyakova V; Hein S; Kostin S; Ziegelhoeffer T; Schaper J
J Am Coll Cardiol; 2004 Oct; 44(8):1609-18. PubMed ID: 15489093
[TBL] [Abstract][Full Text] [Related]
25. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation.
Kandalam V; Basu R; Abraham T; Wang X; Soloway PD; Jaworski DM; Oudit GY; Kassiri Z
Circ Res; 2010 Mar; 106(4):796-808. PubMed ID: 20056917
[TBL] [Abstract][Full Text] [Related]
26. Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig.
Goetzenich A; Hatam N; Zernecke A; Weber C; Czarnotta T; Autschbach R; Christiansen S
J Heart Lung Transplant; 2009 Oct; 28(10):1087-93. PubMed ID: 19782292
[TBL] [Abstract][Full Text] [Related]
27. Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodelling.
Wei Y; Cui C; Lainscak M; Zhang X; Li J; Huang J; Zhang H; Zheng Z; Hu S
J Cell Mol Med; 2011 Apr; 15(4):773-82. PubMed ID: 20219015
[TBL] [Abstract][Full Text] [Related]
28. Integration of concepts: cardiac extracellular matrix remodeling after myocardial infarction.
Cleutjens JP; Creemers EE
J Card Fail; 2002 Dec; 8(6 Suppl):S344-8. PubMed ID: 12555143
[TBL] [Abstract][Full Text] [Related]
29. Transgenic expression of matrix metalloproteinase-1 inhibits myocardial fibrosis and prevents the transition to heart failure in a pressure overload mouse model.
Foronjy RF; Sun J; Lemaitre V; D'Armiento JM
Hypertens Res; 2008 Apr; 31(4):725-35. PubMed ID: 18633185
[TBL] [Abstract][Full Text] [Related]
30. MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure.
Li YY; Kadokami T; Wang P; McTiernan CF; Feldman AM
Am J Physiol Heart Circ Physiol; 2002 Mar; 282(3):H983-9. PubMed ID: 11834496
[TBL] [Abstract][Full Text] [Related]
31. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation.
Nishikawa N; Yamamoto K; Sakata Y; Mano T; Yoshida J; Miwa T; Takeda H; Hori M; Masuyama T
Cardiovasc Res; 2003 Mar; 57(3):766-74. PubMed ID: 12618238
[TBL] [Abstract][Full Text] [Related]
32. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction.
Lindsey ML; Gannon J; Aikawa M; Schoen FJ; Rabkin E; Lopresti-Morrow L; Crawford J; Black S; Libby P; Mitchell PG; Lee RT
Circulation; 2002 Feb; 105(6):753-8. PubMed ID: 11839633
[TBL] [Abstract][Full Text] [Related]
33. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction.
Hayashidani S; Tsutsui H; Shiomi T; Suematsu N; Kinugawa S; Ide T; Wen J; Takeshita A
Circulation; 2002 Feb; 105(7):868-73. PubMed ID: 11854129
[TBL] [Abstract][Full Text] [Related]
34. Extracellular degradative pathways in myocardial remodeling and progression to heart failure.
Spinale FG; Gunasinghe H; Sprunger PD; Baskin JM; Bradham WC
J Card Fail; 2002 Dec; 8(6 Suppl):S332-8. PubMed ID: 12555141
[TBL] [Abstract][Full Text] [Related]
35. Cardiac remodeling and failure From molecules to man (Part II).
Fedak PW; Verma S; Weisel RD; Li RK
Cardiovasc Pathol; 2005; 14(2):49-60. PubMed ID: 15780796
[TBL] [Abstract][Full Text] [Related]
36. Signaling pathways that influence extracellular remodeling.
Lee RT; Lammerding J
J Card Fail; 2002 Dec; 8(6 Suppl):S339-43. PubMed ID: 12555142
[TBL] [Abstract][Full Text] [Related]
37. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation.
Mukherjee R; Herron AR; Lowry AS; Stroud RE; Stroud MR; Wharton JM; Ikonomidis JS; Crumbley AJ; Spinale FG; Gold MR
Am J Cardiol; 2006 Feb; 97(4):532-7. PubMed ID: 16461051
[TBL] [Abstract][Full Text] [Related]
38. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure.
Moore L; Fan D; Basu R; Kandalam V; Kassiri Z
Heart Fail Rev; 2012 Sep; 17(4-5):693-706. PubMed ID: 21717224
[TBL] [Abstract][Full Text] [Related]
39. Expression of the tissue inhibitor of metalloproteinase-3 by transplanted VSMCs modifies heart structure and function after myocardial infarction.
Jia ZB; Tian H; Kang K; Miao HZ; Liu KY; Jiang SL; Wang LP
Transpl Immunol; 2014 May; 30(4):149-58. PubMed ID: 24727088
[TBL] [Abstract][Full Text] [Related]
40. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function.
Spinale FG
Physiol Rev; 2007 Oct; 87(4):1285-342. PubMed ID: 17928585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
